T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Stock Price Today
Aura AI Summary
Key Stats
- $82.36MMarket Cap
- 67,387,505Volume
- Leveraged / InverseSector
- $27.9252W High
- $2.2952W Low
- 9 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 53% Sell | 47% BuyTrading Activity
Track T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, T-Rex 2X Inverse MSTR Daily Target ETF has traded between a low of $2.29 and a high of $27.92, highlighting its annual price range. Buy and sell T-Rex 2X Inverse MSTR Daily Target ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Most Recent News
Axon cuts 2026 revenue forecast after $130M delay in Federal Dedrone deployments, shares drop.
Axon Enterprise lowered its 2026 revenue forecast to $3.61-$3.63 billion on November 5, removing about $130 million due to delays in three Federal Dedrone counter-drone deployments. This revision followed an August 5 forecast increase to 32%-34% grow...

Koppers shares drop after Q3 earnings miss and cut to 2026 guidance sparks investigation.
Koppers Holdings reported an 18% drop in adjusted EBITDA and a 38% decline in net income for Q3 2026, leading to a significant reduction in its full-year adjusted EPS guidance. This triggered a sharp decline in its stock price and prompted a legal in...

Madrigal Pharmaceuticals faces whistleblower claims, stock drops 8% amid alleged data suppression.
Madrigal Pharmaceuticals is under investigation after a whistleblower complaint from a former senior executive accused the company of suppressing adverse safety data and presenting unreliable efficacy results for its drug Rezdiffra. The allegations i...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.